Document is current
Any future updates will be listed below
-
Authors
Wißfeld, Jannis
Mathews, Mona
Mossad, Omar
Picardi, Paola
Cinti, Alessandro
Redaelli, Loredana
Pradier, Laurent
Brüstle, Oliver
Neumann, Harald
-
Funding
Funding for this research was provided by:
Innovative Medicines Initiative 2 Joint Undertaking (Grant agreement No. 115976 (PHAGO))
Innovative Medicines Initiative 2 Joint Undertaking (Grant agreement No. 115976 (PHAGO))
Innovative Medicines Initiative 2 Joint Undertaking (Grant agreement No. 115976 (PHAGO))
Innovative Medicines Initiative 2 Joint Undertaking (Grant agreement No. 115976 (PHAGO))
Innovative Medicines Initiative 2 Joint Undertaking (Grant agreement No. 115976 (PHAGO))
Innovative Medicines Initiative 2 Joint Undertaking (Grant agreement No. 115976 (PHAGO))
Innovative Medicines Initiative 2 Joint Undertaking (Grant agreement No. 115976 (PHAGO))
Innovative Medicines Initiative 2 Joint Undertaking (Grant agreement No. 115976 (PHAGO))
Deutsche Forschungsgemeinschaft (FOR2953 (NE507/16-1 Nr. 432190414))
Rheinische Friedrich-Wilhelms-Universität Bonn
- License Information
-
More Information
Article History
Received: 10 November 2020
Accepted: 7 June 2021
First Online: 29 June 2021
Competing interests
: MM, PP, AC, LR, LP and OB are employed by a company with activities related to the topic of this manuscript. MM and OB are named inventors of a submitted patent related to upscaled production of iPSC-derived microglia and macrophages (EP20162230) that is assigned to the LIFE & BRAIN GmbH. OB and HN are named inventors on a patent related to generation of microglial precursors from pluripotent stem cells (patent family to WO2010125107A1<sup>34</sup>) that is assigned to the LIFE & BRAIN GmbH and the University of Bonn. JW and OM declare no potential conflict of interest.
